Autonomix Medical Inc (AMIX) Q1 2026 Earnings Report

Autonomix Medical Inc (AMIX) reported QQ1 2026 results with no disclosed revenue for the quarter and a substantial operating loss driven by ongoing R&D and administrative investments. The quarter ended 2025-06-30 shows operating expenses of $3.421 million (R&D $1.593 million; G&A $1.829 million) and an EBITDA of -$3.334 million, resulting in an operating loss of -$3.421 million and a net loss of -$3.337 million (EPS -$1.07). While the company is not yet generating revenue, cash from financing activities partially offset cash burn, leaving a modest net cash decrease of $0.547 million for the period and a cash balance of $8.589 million at quarter-end.

From a balance sheet perspective, total assets stood at $8.997 million and total liabilities at $1.965 million, with stockholders’ equity of $7.032 million. Negative retained earnings of -$53.716 million reflect cumulative losses, offset by accumulated other equity components totaling $60.744 million, suggesting continued external funding support typical of a development-stage device company. No debt is reported, and the company remains funded primarily through equity and other comprehensive equity instruments.

Key takeaway: AMIX remains in the pre-commercial phase, exhibiting a meaningful cash burn tied to platform development. The near-term equity-market and clinical/validation milestones will be critical to extending the cash runway and unlocking potential partnerships or licensing opportunities. Absent revenue generation or a clear monetization event, upside hinges on successful data readouts, strategic collaborations, and continued access to capital.